Stallergenes Greer

"I am proud to be part of the team that provides software support and solutions to assist manufacturing in their goals for process improvement and innovation,” Lacey McCaw, Business Intelligence Software Analyst. Lacey works at Stallergenes Greer’s Lenoir (NC) site. She is responsible for gathering business data and studying industry trends to analyze company performance and look for areas of improvement. Every day, Stallergenes Greer colleagues across the globe work together to deliver safe, efficient, and high-quality allergen immunotherapy treatments to improve the quality of life of patients like Will who suffer from respiratory, food or insect venom allergy. #AllergenImmunotherapy #AllergyWeTakeItPersonally #RespiratoryAllergy #FoodAllergy #InsectVenomAllergy

Stallergenes Greer today announced that the U.S. Food and Drug Administration (FDA) has approved Palforzia® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], for the treatment of toddlers (ages 1-3 years) with a confirmed diagnosis of a peanut allergy. This approval expands the January 2020 FDA approval for patients ages 4-17 years. Palforzia® is to date the first and only approved oral immunotherapy treatment (OIT) for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. “We are delighted that Palforzia® has received regulatory approval in the U.S. for toddlers as there is a high unmet medical need for this age group and we are confident that this indication extension will alleviate the burden of peanut allergy for younger patients and their families,” says Elena Rizova, MD, PHD, Chief Medical Officer of Stallergenes Greer. The FDA approval in toddlers is based on data from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study that was published in the New England Journal of Medicine Evidence in 2023. The study evaluated the efficacy and safety of Palforzia® in peanut-allergic children aged 1 to 3 years old, meeting all its primary and secondary efficacy endpoints and demonstrating a favourable safety profile.   Read the full press release here: https://lnkd.in/ex4R8efp

𝗦𝘁𝗮𝗹𝗹𝗲𝗿𝗴𝗲𝗻𝗲𝘀 𝗚𝗿𝗲𝗲𝗿 𝗶𝘀 𝗽𝗿𝗼𝘂𝗱 𝘁𝗼 𝘀𝗽𝗼𝗻𝘀𝗼𝗿 𝘁𝗵𝗲 𝟮𝟬𝟮𝟰 𝗔𝗹𝗹𝗲𝗿𝗴𝗲𝗻 𝗪𝗮𝗹𝗸𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗼𝗳 𝗩𝗲𝘁𝗲𝗿𝗶𝗻𝗮𝗿𝘆 𝗗𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆! Join us for a unique opportunity to deepen your understanding of allergenic pollens in the environment. 🌿 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗮𝗻 𝗔𝗹𝗹𝗲𝗿𝗴𝗲𝗻 𝗪𝗮𝗹𝗸?  An allergen walk introduces participants to the plants that may contribute to their patients’ allergic conditions. Our knowledgeable scientist and botany specialist, Bob Jacobson*, will guide us through the area around the convention center, identifying plants that produce allergenic pollens and explaining their significance in atopic dermatitis. 🌿 𝗞𝗲𝘆 𝗣𝗼𝗶𝗻𝘁𝘀 𝗖𝗼𝘃𝗲𝗿𝗲𝗱: • Pollen production and characteristics • Male and female flowers and their relationship to allergenicity • Seasonality of pollen production by different species • Cross-reactivity of allergens from different species • How pollen is collected and processed into sterile products for testing and treatment • Other allergen sources such as fungi and insects By participating, you’ll gain valuable insights to help you better explain the role of plants and other species in your patients’ allergic signs, helping to educate your pet owners about the pollens that may be affecting their beloved pets. We will embark on our adventures Saturday at 12:15pm-1:15pm and Sunday 6:45am-7:45am, rain or shine. We encourage you to come in comfortable shoes for walking and bring along your camera to take photos of the different species we will encounter along the way! 🌿 𝗔𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 #𝗪𝗖𝗩𝗗𝟭𝟬 𝗮𝗻𝗱 𝘄𝗮𝗻𝘁 𝘁𝗼 𝗮𝘁𝘁𝗲𝗻𝗱 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲𝘀𝗲 𝗯𝗼𝘁𝗮𝗻𝗶𝗰𝗮𝗹 𝗮𝗱𝘃𝗲𝗻𝘁𝘂𝗿𝗲𝘀? Email Sherry Brown at sherry.brown@stallergenesgreer.com and specify which day/time you prefer. 𝗛𝘂𝗿𝗿𝘆! 𝗦𝗽𝗮𝗰𝗲 𝗶𝘀 𝗹𝗶𝗺𝗶𝘁𝗲𝗱! *𝘉𝘰𝘣 𝘑𝘢𝘤𝘰𝘣𝘴𝘰𝘯 𝘪𝘴 𝘣𝘦𝘪𝘯𝘨 𝘤𝘰𝘮𝘱𝘦𝘯𝘴𝘢𝘵𝘦𝘥 𝘣𝘺 𝘚𝘵𝘢𝘭𝘭𝘦𝘳𝘨𝘦𝘯𝘦𝘴 𝘎𝘳𝘦𝘦𝘳 #StallergenesGreer #PetsGetAllergies #WCVD2024 #WCVD10 #AllergenWalks #VeterinaryDermatology #AnimalHealth #Botany #Pollen #Fungi #Insects

𝗦𝘁𝗮𝗹𝗹𝗲𝗿𝗴𝗲𝗻𝗲𝘀 𝗚𝗿𝗲𝗲𝗿 𝗶𝘀 𝗲𝘅𝗰𝗶𝘁𝗲𝗱 𝘁𝗼 𝘀𝗽𝗼𝗻𝘀𝗼𝗿 𝗮𝗻𝗱 𝗮𝘁𝘁𝗲𝗻𝗱 𝘁𝗵𝗲 𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗼𝗳 𝗩𝗲𝘁𝗲𝗿𝗶𝗻𝗮𝗿𝘆 𝗗𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝗶𝗻 𝗕𝗼𝘀𝘁𝗼𝗻, 𝗠𝗔! From July 25-29, we will be joining veterinary practitioners, researchers, and industry leaders from around the world to explore the latest advancements in veterinary dermatology. This event is a fantastic opportunity to share knowledge, network with peers, and discover innovative approaches to enhancing animal health and well-being. We look forward to engaging with fellow professionals, attending insightful sessions, and highlighting our latest products and services designed to support veterinary dermatologists in their vital work of helping animals with atopic dermatitis and other skin diseases. 𝗜𝗳 𝘆𝗼𝘂'𝗿𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗼𝗻𝗴𝗿𝗲𝘀𝘀, 𝗯𝗲 𝘀𝘂𝗿𝗲 𝘁𝗼 𝘃𝗶𝘀𝗶𝘁 𝘂𝘀 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 #𝟮𝟱 – 𝘄𝗲'𝗱 𝗹𝗼𝘃𝗲 𝘁𝗼 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝗮𝗻𝗱 𝗲𝗱𝘂𝗰𝗮𝘁𝗲 𝗼𝗻 𝗮𝗹𝗹𝗲𝗿𝗴𝗲𝗻-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘄𝗶𝘁𝗵𝗶𝗻 𝘆𝗼𝘂𝗿 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲.   #StallergenesGreer #PetsGetAllergies #VeterinaryDermatology #WCVD2024 #WCVD10 #Boston #AnimalHealth #Innovation #VeterinaryMedicine #AllergenSpecificImmunotherapy

Follow the Stallergenes Greer Foundation to stay updated on its ongoing efforts to support groundbreaking allergy research and innovations that benefit patients worldwide! https://lnkd.in/ea2Tt6gk

An abundant harvesting season for sweet vernal, orchard, perennial rye, timothy, and Kentucky blue grass #pollen has come to a close in Amilly (France). Each year several hundred kilograms of raw pollen, which are processed for pharmaceutical #BioProduction, are harvested on our 100 hectares of land in France. At the end of the grass pollen harvest, the forage is collected to be used either as fodder, bedding for animals, or in a biogas digester. These different uses of #GreenWaste are established by contract with local farmers. Every three years, we rotate the plots to preserve their yields and ensure production continuity. At the heart of our commitment to providing relief for people with allergies lies our engagement to supporting the communities where we live and work. Thank you to our team for their hard work and dedication throughout the season! Their work is testament to the excellence of our operations. #AllergyWeTakeItPersonally #CSR #BioProduction #CareBeyondAllergy #TeamWork

We are pleased to announce that our research has achieved significant recognition at #EAACI2024! Dr. Laurent Mascarell, our Head of Innovation and Science, received the Outstanding Flash Talk Presentation Award for his work on “LILRA5 and CCL25 as candidate predictive biomarkers of AIT efficacy.” This research, in collaboration with Prof. Cezmi Akdis and his team, identifies for the first time LILRA5 and CCL25 as key indicators of a patient's inflammatory status, thus offering insights into the potential clinical responses during house dust mite immunotherapy. Dr. Eric Fromentin (Private practice, Lille, France) was awarded for his thematic poster presentation on "Impact of liquid sublingual immunotherapy on asthma worsening prevention: GINA treatment stepping up results from the real-world EfficAPSI study." The research highlights that liquid sublingual immunotherapy significantly reduces (by one-third) the Global Initiative for Asthma (GINA) treatment stepping-up in allergic rhinitis patients with associated asthma, thus demonstrating its ability to prevent asthma worsening and substantiating its evidence as a relevant causal treatment option for patients with respiratory allergies. Pr. Randolf Brehler (University Hospital Münster, Germany) also received an award for his Flash Talk on "Systematic literature review and adjusted indirect treatment comparisons of 2 allergen immunotherapy treatments for grass pollen–induced allergic rhinitis." The research shows that two commercially available grass-pollen tablets have similar short and long-term efficacy in reducing symptoms and medication use in patients with grass pollen-induced allergic rhinitis, regardless of age, thus offering allergic sufferers (and their healthcare providers) the possibility of choosing the treatment that best suits their needs and expectations. These awards are a testament to the hard work, dedication, and excellence of everyone involved in our research and underscore Stallergenes Greer’s commitment to advancing precision medicine for #allergy sufferers. We extend our gratitude to all our collaborators and colleagues who made these achievements possible. Véronique Bordas, Sonia LUCE, Silvia Scurati, Anja Heider and Duygu Yazici #Biomarkers #AllergenImmunotherapy #AsthmaPrevention #PatientCare #AllergyWeTakeItPersonally #PrecisionMedicine #EAACI

#WorldAllergyWeek Deborah and her family live in Chicago (Illinois). Deborah tells us more about discovering that her daughter Zoey was allergic to peanut protein: “Zoey had two accidental exposures to peanut at a very young age. The first time was when she was 11 months old. She was given peanut butter and jelly sticks and, although she was a very good eater, she closed her mouth. It was the first thing she didn’t eat, and we later learned that it was a typical mild first reaction to peanut. The second time was when she was three. We were at a wedding and there were candies on a table. Zoey ate just a bite and experienced severe anaphylaxis. I made the decision to start her with the process of getting the blood work and skin prick tests.” The diagnosis of peanut allergy is complicated as symptoms vary from one person to another. Peanut is present in a variety of foods (baked goods, cereal, salad dressing, candies, meat substitutes, etc.) as well as in non-food products. #AllergyWeTakeItPersonally #Allergies #FoodAllergy #PeanutAllergy

#WorldAllergyWeek runs June 23-29, 2024. This year’s edition is under the banner “Overcoming Food Allergy Obstacles”. #FoodAllergy, which can be life-threatening, is becoming more common in people of all ages. The spread of prevalence data is wide, ranging from 1% to 10%[1]. The increase in food allergy over recent decades strongly implicates environmental factors as a dominant force in determining food allergy risk.[2] The most common foods that cause allergic reactions, whether eaten separately or as an ingredient, even in trace amounts (also known as hidden foods), are milk, egg, fish, shellfish, tree nuts, peanut, wheat, and soybean. Avoidance of the food allergen is the only way to protect against an allergic reaction. Food allergy reactions include a variety of clinical conditions affecting the gastrointestinal tract, skin and lungs, as well as sometimes fatal anaphylaxis.   Peanut allergy is one of the major causes of severe life-threatening allergic reactions [2]. Stallergenes Greer recently added to its portfolio an oral immunotherapy treatment for peanut allergy and is proud to support advancements in allergy treatment, covering both respiratory and food allergies to help address these burdens.     [1]  Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol 2024;153:576-94 [2] Nature Review, Disease Primers. Food allergies. Harald Renz et al. Online: https://lnkd.in/eYpk3Qc8.

We are thrilled to announce that the awards organized by our foundation, were presented during the EAACI Congress.  The five winners had the opportunity to share their work and aspiration in research to an audience of 300 guests from the global allergy community. This event highlights the importance of looking toward the future. We are proud to support the next generation of researchers and scientists, fostering innovation and excellence in the field of allergy research. Congratulations to all the winners! Together, we are making strides in the fight against allergies and paving the way for groundbreaking discoveries. #EAACI2024 #ScienceAwardsForAllergy #AllergyResearch #FutureofScience